STRUCTURED NOTE PROGRAMME BASE PROSPECTUS SUPPLEMENT (No.7) dated 17 December 2019



CITIGROUP GLOBAL MARKETS HOLDINGS INC. (a corporation duly incorporated and existing under the laws of the State of New York)

the issuer under the Citi U.S.\$10,000,000,000 Global Structured Note Programme

Notes issued by Citigroup Global Markets Holdings Inc. will be unconditionally and irrevocably guaranteed by CITIGROUP INC. (incorporated in Delaware)

This base prospectus supplement (the "**Supplement**") constitutes a supplement for the purposes of Article 16 of Directive 2003/71/EC, as amended or superseded (the "**Prospectus Directive**") as implemented in Ireland by the Prospectus (Directive 2003/71/EC) Regulations 2005 (as amended by the Prospectus (Directive 2003/71/EC) Amending Regulations 2012) and is supplemental to, and must be read in conjunction with, the Structured Note Programme Base Prospectus dated 8 February 2019, as supplemented by a Supplement (No.1) dated 20 March 2019, a Supplement (No.2) dated 16 May 2019, a Supplement (No.3) dated 7 June 2019, a Supplement (No.4) dated 8 August 2019, a Supplement (No.5) dated 23 September 2019 and a Supplement (No.6) dated 7 November 2019 (each a "**Previous Supplement**") (the "**Base Prospectus**") with respect to the Citi U.S.\$10,000,000,000 Global Structured Note Programme (the "**Programme**").

Terms defined in the Base Prospectus shall, unless the context otherwise requires, have the same meaning when used in this Supplement. References in this Supplement to page numbers in the Base Prospectus are to the page numbers in the Base Prospectus without taking into account any amendments made in the Previous Supplements.

This Supplement has been approved by the Central Bank of Ireland (the "**Central Bank**"), as competent authority under the Prospectus Directive. The Central Bank only approves this Supplement as meeting the requirements imposed under Irish and EU law pursuant to the Prospectus Directive.

Application has been made to the Irish Stock Exchange plc trading as Euronext Dublin ("**Euronext Dublin**") for the approval of this Supplement as a Base Listing Particulars Supplement (the "**BLP Supplement**"). Save where expressly provided or the context otherwise requires, where Notes are to be admitted to trading on the Global Exchange Market references herein to "Supplement" shall be construed to be to "BLP Supplement".

CGMHI accepts responsibility for the information contained in this Supplement. To the best of the knowledge of CGMHI (having taken all reasonable care to ensure that such is the case), the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

The CGMHI Guarantor accepts responsibility for the information contained in this Supplement (excluding (i) the paragraphs under the heading "*Information relating to the Base Prospectus*" below. To the best of the knowledge of the CGMHI Guarantor (having taken all reasonable care to ensure that such is the case), the information contained in this Supplement (with the exception of the aforementioned excluded information) is in accordance with the facts and does not omit anything likely to affect the import of such information.

INFORMATION RELATING TO THE BASE PROSPECTUS

Publication of the 2019 Q3 Form 10-Q of Citigroup Inc. on 1 November 2019

On 1 November 2019, Citigroup Inc. (as an Issuer under the Programme) filed its Quarterly Report on Form 10-Q (the "**Citigroup Inc. 2019 Q3 Form 10-Q**") for the three and nine months ended 30 September 2019with the Securities and Exchange Commission of the United States (the "**SEC**"). A copy of the Citigroup Inc. 2019 Q3 Form 10-Qhas been filed with the Central Bank, Euronext Dublin and the *Commission de Surveillance du Secteur Financier* (the "**CSSF**") and has been published on the website of the Luxembourg Stock Exchange. (https://dl.bourse.lu/dl?v=waNgpee1o3dsnNh4NbSrCCi8qUhdBNS5yrCayjlX+mvsOZ/S8ttoc6rN3auiJ6LyFYk ERTGBLXS4kkR4Xqu9ydaPJCon42MzrKNtQ11xwJ4bGuzpyy2bd2Iu/rVgcqzbAPD8VXff+gtnH2eZBmoFhuq GTwbBWHWgS0fYedicjQMb7KI+GXpVzuZw5cYDorzgbYuutCIwQ9PObaH7t3BGTgBIBjVxQZKAe9F1mb ECnayrRfjlkb+e/9IUkzkeBjZozCnmjMBUS6Bdc5svH0qtvw). By virtue of this Supplement, the Citigroup Inc. 2019 Q3 Form 10-Q is incorporated by reference in, and forms part of the Structured Note Programme Base Prospectus.

The following information appears on the page(s) of the Citigroup Inc. 2019 Q3 Form 10-Q as set out below:

1. Unaudited interim financial information of Citigroup Inc. in respect of the three and nine months ended 30 September 2019, as set out in the Citigroup Inc. 2019 Q3 Form 10-Q:

		Page(s)
(a)	Consolidated Statements of Income and Comprehensive Income	80-81
(b)	Consolidated Balance Sheet	82-83
(c)	Consolidated Statement of Changes in Stockholders' Equity	84-85
(d)	Consolidated Statement of Cash Flows	86-87
(e)	Notes to the Consolidated Financial Statements	88-201
2.	Other information relating to Citigroup Inc., as set out in the Citigroup Inc. 2019 Q3 Form 10-Q:	
		Page(s)
(a)	Description of the principal activities of Citigroup Inc.	Page(s) 1-22
(a) (b)	Description of the principal activities of Citigroup Inc. Description of the principal markets in which Citigroup Inc. competes	
. /	Description of the principal markets in which Citigroup Inc.	1-22
(b)	Description of the principal markets in which Citigroup Inc. competes	1-22 2, 8-22
(b) (c)	Description of the principal markets in which Citigroup Inc. competes Description of the principal investments of Citigroup Inc.	1-22 2, 8-22 104-117

Any information not listed in the cross-reference list above but included in the Citigroup Inc. 2019 Q3 Form 10-Q is given for information purposes only.

Alternative Performance Measures

Information relating to alternative performance measures ("**APMs**") for the purposes of the Guidelines published by the European Securities and Markets Authority ("**ESMA**") is set out in the Schedule to this Supplement.

Significant change and material adverse change

There has been no significant change in the financial or trading position of Citigroup Inc. or Citigroup Inc. and its subsidiaries as a whole since 30 September 2019 (the date of Citigroup Inc.'s most recently published unaudited interim financial statements), and there has been no material adverse change in the financial position or prospects of Citigroup Inc. or Citigroup Inc. and its subsidiaries as a whole since 31 December 2018 (the date of Citigroup Inc.'s most recently published addited annual financial statements).

Legal proceedings

For a discussion of CGMHI's material legal and regulatory matters, see Note 16 to the Consolidated Financial Statements included in the CGMHI 2018 Annual Report and Note 13 to the Consolidated Financial Statements included in the CGMHI 2019 Half-Yearly Financial Report. For a discussion of Citigroup Inc.'s material legal and regulatory matters, of which the matters discussed in Notes 16 and 13 (as specified above) are a part, see (i) Note 27 to the Consolidated Financial Statements included in the Citigroup Inc. 2018 Form 10-K, (ii) Note 23 to the Consolidated Financial Statements included in the Citigroup Inc. 2019 Q1 Form 10-Q, (iii) Note 23 to the Consolidated Financial Statements included in the Citigroup Inc. 2019 Q2 Form 10-Q and (iv) Note 23 to the Consolidated Financial Statements included in the Citigroup Inc. 2019 Q3 Form 10-Q. Save as disclosed in the documents referenced above, neither CGMHI nor any of its subsidiaries is involved in, or has been involved in, any governmental, legal or arbitration proceedings that may have had in the twelve months before the date of this Supplement, a significant effect on the financial position or profitability of CGMHI or CGMHI and its subsidiaries taken as a whole, nor, so far as CGMHI is aware, are any such proceedings pending or threatened.

For a discussion of Citigroup Inc.'s material legal and regulatory matters, see (i) Note 27 to the Consolidated Financial Statements included in the Citigroup Inc. 2018 Form 10-K, (ii) Note 23 to the Consolidated Financial Statements included in the Citigroup Inc. 2019 Q1 Form 10-Q, (iii) Note 23 to the Consolidated Financial Statements included in the Citigroup Inc. 2019 Q2 Form 10-Q and (iv) Note 23 to the Consolidated Financial Statements included in the Citigroup Inc. 2019 Q3 Form 10-Q. Save as disclosed in the documents referenced above, neither Citigroup Inc. nor any of its subsidiaries is involved in, or has been involved in, any governmental, legal or arbitration proceedings that may have had, in the twelve months before the date of this Supplement, a material effect on the financial position or profitability of Citigroup Inc. or Citigroup Inc. and its subsidiaries as a whole, nor, so far as Citigroup Inc. is aware, are any such proceedings pending or threatened.

General

Save as disclosed in this Supplement (including any documents incorporated by reference herein), there has been no other significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus since the publication of the last Previous Supplement.

For so long as the Programme remains in effect or any Notes remain outstanding, copies of the Base Prospectus and this Supplement will be available for inspection in electronic form and at the specified office of the Fiscal Agent and each of the other Paying Agents and all documents incorporated by reference in the Base Prospectus will be available on the website specified for each such document in the Base Prospectus.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any statement in the Base Prospectus or otherwise incorporated by reference into the Base Prospectus, the statements in (a) above will prevail.

SCHEDULE

ALTERNATIVE PERFORMANCE MEASURES (CITIGROUP INC. 2019 Q3 FORM 10-Q)

The Citigroup Inc. 2019 Q3 Form 10-Q contains certain alternative performance measures (APMs). For further details on the components of the APMs, how these APMs are calculated, an explanation of why such APMs provide useful information for investors and a reconciliation to the nearest equivalent US GAAP measures, please see references to "Non-GAAP Financial Measures" in the Citigroup Inc. 2019 Q3 Form 10-Q and the table below:

АРМ	Explanation of why use of APM provides useful information	Citigroup Inc. 2019 Q3 Form 10-Q Page Reference for Basis of Calculation, Components, Reconciliation and Comparatives to Previous Reporting Periods
Results of Operations Excluding the impact of Foreign Exchange Translation	1 1	Pages 3 to 5, 11, 14 to 17, 20 to 21, 52 and 60
Tangible Common Equity and Tangible Book Value per Share	Citi believes these capital metrics provide useful information, as they are used by investors and industry analysts.	Pages 7 and 35
Return on Tangible Common Equity	Citi believes these capital metrics provide useful information for investors and industry analysts.	Pages 7 and 35
Results of Operations Excluding the Impact of gains/ (losses) on Loan Hedges	Citi believes the presentation of its results of operations excluding the impact of gain/(loss) on loan hedges related to accrual loans provides a more meaningful depiction for investors of the underlying fundamentals of its businesses.	Pages 4, 19 to 21

АРМ	Explanation of why use of APM provides useful information	Citigroup Inc. 2019 Q3 Form 10-Q Page Reference for Basis of Calculation, Components, Reconciliation and Comparatives to Previous Reporting Periods
Results Excluding the Impact of Certain Gains and Sales	Citi believes the presentation of the Results Excluding the Impact of certain gains and sales provide a more meaningful depiction for investors of the underlying fundamentals of its business	Pages 4 and 15